๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease

โœ Scribed by Quincy J. Almeida; James S. Frank; Eric A. Roy; Aftab E. Patla; Mandar S. Jog


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
242 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

The basal ganglia have been implicated in timing control, yet the nature of timing disturbances in Parkinson's disease (PD) is poorly understood. We evaluated the influence of timing cues on spatiotemporal aspects of gait control and its variability, and the impact of dopaminergic treatment on timing. Three separate groups: 19 PD (OFF state); 24 PD (ON state); and 30 control participants were tested. Participants walked on a computerized carpet at four randomized and metronomeโ€controlled rates: selfโ€paced, 60, 80, or 100 steps/min. To our knowledge, this is the first study to demonstrate that medicated PD patients had poorer timing control than patients withdrawn from medication and healthy participants when modulating timing to an external stimulus. Increased stepโ€toโ€step timing variability and deficits in mean temporal gait characteristics revealed that the medicated PD group (in contrast to nonmedicated PD group) performed least like healthy participants. This was observable in externallyโ€cued conditions, but not during selfโ€paced gait. Similar to previous research, step length contributed to overall slowness in PD, while temporal characteristics of gait did not. Interestingly, healthy participants increased stride length with each increase in cue rate, whereas both PD groups locked their step length regardless of temporal demand. Stepโ€toโ€step variability differences between PD and healthy (e.g. step and doubleโ€support time measurements) may be indicative of specific basal ganglia involvement in temporal control of gait. ยฉ 2007 Movement Disorder Society


๐Ÿ“œ SIMILAR VOLUMES


Dopaminergic modulation of cortical func
โœ Venkata S. Mattay; Alessandro Tessitore; Joseph H. Callicott; Alessandro Bertoli ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 399 KB ๐Ÿ‘ 2 views

## Abstract Patients with idiopathic Parkinson's disease suffer not only from classic motor symptoms, but from deficits in cognitive function, primarily those subserved by the prefrontal cortex as well. The aim of the current study was to investigate the modulatory effects of dopaminergic therapy o

The clinical spectrum of freezing of gai
โœ Yasuyuki Okuma; Nobuo Yanagisawa ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 60 KB ๐Ÿ‘ 1 views

Freezing of gait (FOG) is a common and very disabling symptom in Parkinson's disease (PD). It is usually observed in the advanced stage of the disease, although a mild form can be seen in the early stage. Although some studies have suggested that longer duration of dopaminergic treatment is associat

Dopaminergic innervation of the human st
โœ Michelle Porritt; Davor Stanic; David Finkelstein; Peter Batchelor; Sharon Lockh ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 308 KB ๐Ÿ‘ 1 views

## Abstract In Parkinson's disease (PD), dopaminergic input to the caudate nucleus and a band of putaminal tissue abutting the external globus pallidus seems well preserved on immunohistochemical staining for the dopamine transporter. Counting of dopaminergic terminals showed that terminal density

Predictors of time to requiring dopamine
โœ Connie Marras; Michael P. McDermott; Ken Marek; Paula Rochon; Gary Naglie; Carol ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 101 KB ๐Ÿ‘ 1 views

## Abstract The rate of progression of Parkinson's disease (PD) is highly variable. Knowledge of factors associated with disease milestones and commonly used research outcome measures helps with patient counseling and guides the design and interpretation of clinical studies. The objective of the st